Search
Displaying 391–400 of 526 for “Retinitis pigmentosa”
-
RD Fund Participates in a €75 Million Series B for SparingVision
In the PressProceeds to fund first, in-human trials of breakthrough gene-agnostic therapy products and advance CRISPR-based genome editing portfolio.
-
Foundation Fighting Blindness to Host VISIONS 2024 Conference
Foundation NewsThe global conference, held on June 21–22, is dedicated to fostering connection, learning, and empowerment for individuals and families impacted by blinding diseases.
-
Foundation News
Collaboration will add a new multi-gene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness.
-
The Retinal Degeneration Fund invests in a $78M Series B for Perceive Biotherapeutics
In the PressThe investment supports the clinical development of two novel programs, both with the aim of being protective against vision loss.
-
Foundation News
The Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for retinal degenerative diseases, will host an online continuing medical education (CME and COPE) course on inherited retinal disease gene therapies on Thursday, June 9, 2022, at 7:00 p.m. EDT.
-
VISIONS 2022, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
In the PressDevelopment of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
-
Foundation News
My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S.
-
Foundation News
Known as Pro-EYS, the study will help researchers design clinical trials for potential therapies
